KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Kairos Pharma, LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.57−0.03 (-5.19%)
Close on Oct 19, 2026
- Market cap
- $12.21M
- P/E (TTM)
- –
- Dividend yield
- –
Kairos Pharma, LTD. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q4 24 | % of revenue |
|---|---|---|---|---|---|---|
| Item 4 [Member] | $50.00M | $50.00M | $50.00M | $50.00M | $50.00M | 100.0% |
| Item One And Two [Member] | – | – | – | – | $5.00M | – |
| Item 1, 2 and 3 [Member] | – | – | $5.00M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Kairos Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.